Phargentis achieves positive results in pilot PK study of its new generic version of COPD treatment indacaterol/glycopyrronium plus DPI device
Phargentis announces another important milestone in achieving positive results in the clinical pilot study of ‘Glide’, its new generic version of COPD treatment indacaterol/glycopyrronium plus Dry Powder Inhaler. The clinical study demonstrated good comparability between ‘Glide’ and originator product Ultibro®Breezhaler®. Phargentis will now proceed to the next pivotal phase of development, on schedule. Global sales of Ultibro[®]Breezhaler[®][ ]exceed 500 MUSD a year.Phargentis has entered the clinical development phase for its second generic inhalation product – the COPD therapy containing